LYMPHOID NEOPLASIA Tcl1 interacts with Atm and enhances NF- B activation in hematologic malignancies

نویسندگان

  • Eugenio Gaudio
  • Riccardo Spizzo
  • Francesco Paduano
  • Zhenghua Luo
  • Alexey Efanov
  • Alexey Palamarchuk
  • Amanda S. Leber
  • Mohamed Kaou
  • Nicola Zanesi
  • Arianna Bottoni
  • Stefan Costinean
  • Laura Z. Rassenti
  • Tatsuya Nakamura
  • Thomas J. Kipps
  • Rami I. Aqeilan
  • Yuri Pekarsky
  • Francesco Trapasso
  • Carlo M. Croce
چکیده

1Department of Molecular Immunology, Virology and Medical Genetics, The Ohio State University, Columbus, OH; 2Department of Experimental and Clinical Medicine, University Magna Græcia of Catanzaro, Catanzaro, Italy; 3Division of Experimental Oncology 2 Centro di Riferimento Oncologico, Aviano, Italy; 4Department of Medicine, University of California at San Diego, La Jolla, CA; and 5Lautenberg Center for Immunology and Cancer Research, Institute for Medical Research, Hebrew University, Jerusalem, Israel

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies.

The T-cell leukemia/lymphoma 1 (TCL1) oncogene is a target of chromosomal translocations and inversions at 14q31.2, and its rearrangement in T cells causes T-cell prolymphocytic leukemias. TCL1 dysregulation in B cells is responsible for the development of an aggressive form of chronic lymphocytic leukemia (CLL), the most common human leukemia. We have investigated the mechanisms underlying the...

متن کامل

LYMPHOID NEOPLASIA High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia

Although activation of the B-cell receptor (BCR) signaling pathway is implicated in the pathogenesis of chronic lymphocytic leukemia (CLL), its clinical impact and the molecular correlates of such response are not clearly defined. T-cell leukemia 1 (TCL1), the AKT modulator and protooncogene, is differentially expressed in CLL and linked to its pathogenesis based on CD5 B-cell expansions arisin...

متن کامل

Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL).

B-cell chronic lymphocytic leukemia (CLL) is the most common human leukemia. Deregulation of the T-cell leukemia/lymphoma 1 oncogene (TCL1) in mouse B cells causes a CD5(+) leukemia similar to aggressive human CLL. To examine the mechanisms by which Tcl1 protein exerts its oncogenic activity in B cells, we performed proteomics experiments to identify its interacting partners. We found that Tcl1...

متن کامل

ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein.

The multiplicity of transcription factors involved in hematologic malignancies suggests a complicated scenario in which many different molecular mechanisms lead to malignant transformation. We hypothesized that some of these proteins might physically and functionally interact and thus mechanistically link different diseases. The ETO protein of t(8;21) acute myeloid leukemia (AML) is an excellen...

متن کامل

Classical and Alternative NF-kB Activation Pathways and Their Roles in Lymphoid Malignancies

Nuclear factor-kB (NF-kB) is a family of highly regulated dimeric transcription factors that play pivotal roles in inflammatory responses and immunological reactions. Although they are often activated concurrently, classical and alternative NF-kB activation pathways have distinct regulatory functions, producing secondary inflammatory responses and regulating lymphoid organ development, respecti...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2011